This is an automatically translated article.
Melanov-m belongs to the group of hormonal drugs containing 80mg of gliclazide and 500mg of metformin hydrochloride. So what does Melanov-m do?
1. What is Melanov-m? The effect of the drug Melanov-m
Melanov-m is effective in the treatment of non-insulin-dependent diabetes mellitus and diabetes mellitus in adults with or without obesity. A single oral dose of 40-120 mg causes a cmax of 2.2-8 mg/liter within 2-8 hours. Unstable drug concentrations are reached after 2 days of using 40-120mg. Taking Melanov-m with food will reduce cmax and slow tmax. The volume of distribution is low due to high serum protein binding of 85-97%. The half-life of Melanov-m 80mg varies from 8.1 to 20.5 hours after a single dose. Melanov-m is mainly metabolized to 7 metabolites and is excreted mainly in the urine and most of the metabolites are carboxylic acid derivatives, up to 60-70% of the dose is excreted in the urine and 10-70% of the dose is excreted in the urine. 20% is excreted in the feces.
Metformin has 50-60% oral bioavailability, complete absorption in the gastrointestinal tract and intestine after 6 hours and rapidly distributed in the body after absorption. Metformin is eliminated by the kidneys in two phases: 95% of absorbed metformin is eliminated in the initial phase with a half-life of 6 hours and the remaining 5% is eliminated slowly in the terminal phase with a half-life of 20 hours. Of these, metformin is not bound to plasma proteins and 40-60% of the dose is detected unchanged in the urine and 30% is detected as unchanged in the faeces. In addition, gliclazide is a hypoglycemic sulfamide, an oral antidiabetic drug. The nitrogen-containing heterocyclic gliclazide molecule gives the drug its distinctive properties from other sulfonylureas. Gliclazide lowers blood glucose by stimulating insulin secretion from the beta cells of the islets of langerhans. In patients with type 2 diabetes, gliclazide restores early peak insulin secretion in the presence of glucose and increases second-phase insulin secretion, resulting in a significant increase in insulin secretion observed after a meal or when drink sugar.
In addition, some other effects of the drug are not listed on the approved drug label, but in some cases the doctor may prescribe Melanov-m 80mg. Therefore, before using the drug, consult your doctor.
2. How to use the drug Melanov-m
The drug Melanov-m is in the form of tablets. Dosage will be based on the condition and age of the patient. Usually take 1-2 tablets / time, take 1-2 times a day with meals with a maximum dose of 4 tablets per day. To use the medicine safely, take Melanov-m exactly as directed by your doctor, do not use more, smaller or longer than prescribed.
3. Undesirable effects when using the drug Melanov-m
Melanov-m medicine can cause some unwanted and common side effects that can be mentioned as:
Nausea, vomiting, diarrhea Stomach pain Constipation Metallic taste in mouth Rash Itching Urticaria Erythema red Headache Dizziness Decreased absorption of vitamin B12 and folic acid has occurred with prolonged use of metformin
4. Some notes when using the drug Melanov-m
Some notes when using Melanov-m include:
Allergy notice to Melanov-m 80mg hypersensitivity reaction to any other allergy. Melanov-m may contain ingredients that are inactive and could cause allergic reactions or other serious problems. Report any medications you are taking including prescription and nonprescription drugs, herbs and supplements, foods, dyes or preservatives. Melanov-m is contraindicated in patients with insulin-dependent diabetes mellitus, renal or hepatic impairment, non-insulin dependent diabetes mellitus with severe complications due to ketoacidosis or acidosis, coma or pre-coma, alcoholism. , patients who have just undergone surgery, infection or trauma, coronary heart disease, heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, pregnant women. Adjust dose based on blood and urine glucose levels during the first few months. However, there are few reports of lactic acidosis in patients with liver or kidney disease. Use of Melanov-m 80 mg in pediatric patients: Safety and efficacy in children have not been established. Hypoglycemia can occur if the patient's diet is reduced, after an accidental or intentional overdose or after intense exercise, trauma and stress. Symptoms of hypoglycemia can be treated by prescribing the patient's meal plan. The drug should be discontinued as soon as signs and symptoms of hypoglycaemia occur. If you forget to take a dose of Melanov-m, take it again as soon as possible. However, if it is close to the time of your next dose, skip the missed dose and continue taking or injecting the medicine as scheduled. Do not use more drug than the treatment regimen. Melanov-m overdose or ingestion can cause serious symptoms such as nausea, vomiting, abdominal pain, shortness of breath, fainting,...
5. Drug interactions
Some drugs that can interact with Melanov-m include:
Diuretics, barbiturates, phenytoin, rifampicin, corticosteroids, estrogens, estroprogestogens and purified progestogens that may decrease glycemic control. The hypoglycemic effect may be enhanced by salicylates, phenylbutazone, sulphonamides, beta-blockers, clofibric acid, vitamin K antagonists, allopurinol, theophylline, caffeine and MAO inhibitors. Concomitant use of miconazole, perhexiline or cimetidine with gliclazide may cause hypoglycaemia. Gliclazide should not be used with drugs that may increase blood glucose levels without close monitoring of blood glucose levels to avoid hyperglycemia. Acarbose and guar gum have been shown to significantly reduce the oral bioavailability of metformin.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
